Meet Luke, age 12
Amenable to exon 53 skipping

About VYONDYS 53

How will I know if my child can be treated with VYONDYS 53?

A doctor will need to interpret the test results to consider appropriate treatment options. Learn more about deletions.

Who is VYONDYS 53 for?

VYONDYS 53 is used to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation in the dystrophin gene that can be treated by skipping exon 53. Learn how gene mutations are identified.

 

VYONDYS 53 is used to treat patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene that can be treated by skipping exon 53.


This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

Has VYONDYS 53 been tested?

Yes. VYONDYS 53 has been studied in clinical trials. See the results from clinical trials.

Is the treatment effective?

Weekly infusions of VYONDYS 53 helped the body make a shorter form of the dystrophin protein in some boys. View the results from clinical studies.

VYONDYS 53 is used to treat patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene that can be treated by skipping exon 53.

This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

How does exon skipping work?

Exon skipping allows the body to make a shorter form of the dystrophin protein.  Learn more about exon skipping.

Genetic Testing

Why is genetic testing important?

A genetic test will confirm a diagnosis of Duchenne and allow your child’s doctor to identify the genetic mutation, so treatment options can be considered, and to assist with family planning. Understanding genetic testing.

What does “amenable” mean?

Amenability describes the potential for your child to be treated with exon-skipping therapy. VYONDYS 53 is only for those whose Duchenne muscular dystrophy is the result of a genetic mutation amenable to exon 53 skipping. Find out more about genetic testing for Duchenne.

Where do I get a genetic test?

If your child has been diagnosed with Duchenne, you can request a genetic test through your child’s doctor. Once you have the results, your doctor or a genetic counselor can interpret them for you. Find out more about genetic testing for Duchenne.

We have a genetic test. How do I know if my child can be treated with VYONDYS 53?

A doctor will need to interpret the test results to consider appropriate treatment options. Learn more about deletions.

How is a genetic test done?

Getting a genetic test is usually as simple as providing a blood or saliva sample. Find out more about genetic testing for Duchenne.

What is a genetic mutation?

A mutation is a change in a person’s DNA. Mutations range in size from a small (a single rung on a ladder) to a large segment of DNA. Every mutation causes a different effect on our bodies. Learn more about the role of genetics in Duchenne.

What is a deletion?

A deletion is a type of mutation where genetic material is missing. Duchenne is caused by a mutation on the dystrophin gene; the mutation may be a deletion, duplication, or other change in the gene.  Learn about genetic testing for Duchenne.

Why is a Duchenne diagnosis important?

Because Duchenne is a progressive disease, it’s important for your child’s doctor to confirm a diagnosis and identify the specific genetic mutation to guide your child’s care and treatment. More about the steps to diagnosis.

My child has a deletion and is missing exon 53. Can they take VYONDYS 53?

Please discuss your child’s genetic test results and treatment options with your child’s doctor. For VYONDYS 53 to work, exon 53 must be present in the dystrophin gene. Your child’s doctor or a genetic counselor is the best person to help you understand genetic testing. Explore what genetic test results can tell you.

VYONDYS 53 Treatment

Who can take VYONDYS 53?

Duchenne patients who receive VYONDYS 53 must have a genetic test that shows a mutation in the dystrophin gene that can be treated by skipping exon 53. Your child's doctor is best equipped to determine if your child’s mutation is amenable to treatment with VYONDYS 53. We’ve developed a Doctor Discussion Guide to help you start that important conversation.

How is VYONDYS 53 given?

VYONDYS 53 therapy is a weekly intravenous (IV) infusion that is always given by a healthcare provider. The medicine is usually infused over 35-60 minutes. Learn more about planning for treatment.

Where will I get my infusion?

Infusions can be given at an infusion center, doctor's office, or your home. Discuss your options with your doctor—there are many factors to consider when deciding what’s best for your family.

What happens if I miss an infusion?

Talk to your healthcare provider. If you miss a dose of VYONDYS 53, it may be administered as soon as possible after the scheduled time.

Should I continue taking my other medications while on VYONDYS 53?

You should talk to your doctor about all the medications you are taking. Your doctor is the best person to advise you about your medicines.

How much VYONDYS 53 will I receive?

The amount of VYONDYS 53 is based upon how much you weigh. The recommended dosage is 30 milligrams per kilogram of body weight, once weekly.

About SareptAssist

How do I get started on VYONDYS 53?

When your child is prescribed VYONDYS 53, we’ll connect you with a SareptAssist dedicated Case Manager. They will provide support to get you started on treatment and throughout your journey—from helping you understand insurance benefits to providing information on treatment locations. How SareptAssist can help.

What is SareptAssist?

SareptAssist is our patient support program. Families are connected with dedicated Case Managers who provide information and support to help them start and stay on treatment with VYONDYS 53. How SareptAssist can help.

What support is available for people being treated with VYONDYS 53?

We developed SareptAssist, our patient support program, to help patients start and stay on therapy. You’ll have support at every step—from managing insurance approvals to coordinating drug delivery.  How SareptAssist can help.

How can I connect with other families of children with Duchenne?

Several advocacy organizations offer Duchenne patients and families the opportunity to come together at events throughout the year. Find out more about Duchenne advocacy groups.

Will my insurance cover VYONDYS 53?

Once your child is prescribed VYONDYS 53, you may enroll in SareptAssist, our patient support program. Your Case Manager will start a benefits investigation of your current insurance plan and can help explain details about your coverage. How SareptAssist can help.

Ongoing support and information from Sarepta.

Sign Up

Image
Icon Signup tips

Receive future tips and support about treatment with VYONDYS 53.

Image
Icon Signup Informed

Stay informed about SareptAssist services.

Image
An icon of 3 people and a circle

Find out about patient resources that are available.

Image
icon-signup-updates

Get updates about news and research on Duchenne from Sarepta.

WHAT IS VYONDYS 53 (golodirsen)?

VYONDYS 53 is used to treat patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene that can be treated by skipping exon 53.

This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

Read More

IMPORTANT RISK INFORMATION

Allergic reactions, including rash, fever, itching, hives, and inflammation and/or peeling of the skin have occurred in patients who were treated with VYONDYS 53. Seek immediate medical care if signs and symptoms of allergic reactions occur.

Damage to the kidneys was seen in animals who received golodirsen. Although damage to the kidneys was not seen in clinical studies with VYONDYS 53, potentially fatal kidney damage has occurred with other drugs that work in a similar way. Your doctor may recommend urine and blood testing before starting treatment followed by urine testing every month and a blood test every 3 months to monitor your kidneys.

IMPORTANT RISK INFORMATION

Allergic reactions, including rash, fever, itching, hives, and inflammation and/or peeling of the skin have occurred in patients who were treated with VYONDYS 53.  Seek immediate medical care if signs and symptoms of allergic reactions occur.

Damage to the kidneys was seen in animals who received golodirsen. Although damage to the kidneys was not seen in clinical studies with VYONDYS 53, potentially fatal kidney damage has occurred with other drugs that work in a similar way. Your doctor may recommend urine and blood testing before starting treatment followed by urine testing every month and a blood test every 3 months to monitor your kidneys.

Adverse reactions that have occurred in at least 20% of patients treated with VYONDYS 53 and more often than in patients who received an inactive intravenous (IV) infusion were headache (41%, 10%), fever (41%, 14%), fall (29%, 19%), pain in the abdomen (27%, 10%), infection of the nose and throat (27%, 14%), cough (27%, 19%), vomiting (27%, 19%), and nausea (20%, 10%).

Other adverse reactions that occurred in greater than 5% of patients treated with VYONDYS 53 and more often than in patients who received an inactive IV infusion were pain at the IV site, back pain, pain, diarrhea, dizziness, stretch or tear in a ligament, bruising, flu, pain in the mouth and throat, stuffy or runny nose, scrapes or scratches of the skin, ear infection, seasonal allergy, fast heartbeat, reactions related to the IV catheter site, constipation, and broken bones.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).

Please see the full Prescribing Information for VYONDYS 53 (golodirsen).